Any practitioner with an active DEA registration can now prescribe buprenorphine for opioid use disorder. That includes physicians (MDs and DOs), nurse practitioners, and physician assistants. The special waiver that used to limit who could prescribe this medication was eliminated in late 2022, opening the door for far more providers to offer it.
What Changed in 2023
For nearly two decades, prescribing buprenorphine for opioid use disorder required a special federal waiver, commonly called the “X-waiver.” Providers had to apply through SAMHSA, complete specific training, and were capped at treating 30, 100, or 275 patients at a time depending on their experience and credentials. This created a bottleneck: even willing providers often skipped the paperwork, leaving many patients without access to treatment.
The Consolidated Appropriations Act of 2023 changed that. Section 1262 repealed the X-waiver requirement entirely, and SAMHSA immediately stopped accepting waiver applications. At the same time, all federal patient caps were eliminated. There is no longer any limit under federal law on how many patients a single practitioner can treat with buprenorphine for opioid use disorder.
Who Qualifies to Prescribe
The short answer: any healthcare provider who holds a DEA registration to prescribe controlled substances. In practice, this means:
- Physicians (MDs and DOs) in any specialty
- Nurse practitioners (NPs)
- Physician assistants (PAs)
You do not need to be an addiction specialist. A family medicine doctor, an internist, or an emergency physician can all write a buprenorphine prescription for opioid use disorder as long as they have a valid DEA number. Board certification in addiction medicine or addiction psychiatry is one pathway, but it’s not the only one.
Training Requirements for DEA Registration
While the old waiver is gone, a new training requirement took its place starting June 27, 2023. Anyone applying for a new DEA registration or renewing an existing one must meet at least one of three criteria:
- Eight hours of training on opioid or other substance use disorders from an approved organization
- Board certification in addiction medicine or addiction psychiatry
- Recent graduation (within five years) from a medical, nursing, or physician assistant program that included at least eight hours of substance use disorder coursework
This training requirement applies broadly to all practitioners prescribing Schedule II through V controlled substances, not just buprenorphine. So if you’re renewing your DEA license to prescribe any controlled medication, you’ll need to check this box regardless.
State Laws Still Vary
Federal law sets the floor, but individual states can add their own restrictions, particularly for nurse practitioners and physician assistants. Some states grant NPs full independent prescribing authority for buprenorphine, while others require physician oversight, at least for a transition period.
A MACPAC analysis found that only about 18 states plus the District of Columbia gave NPs full prescriptive authority. The remaining states either imposed permanent physician supervision requirements or required a transition period during which NPs could only prescribe under a physician’s oversight before eventually practicing independently. States like Texas, Florida, New York, California, and Ohio fall into the restricted category. If you’re an NP or PA, checking your state’s specific scope-of-practice rules is essential before prescribing.
Office-Based vs. Opioid Treatment Programs
One of the biggest advantages of buprenorphine over methadone is that it can be prescribed in a regular doctor’s office. A patient can walk into a primary care visit, receive a prescription, and fill it at a pharmacy. This is sometimes called office-based opioid treatment.
Buprenorphine is also available at SAMHSA-certified opioid treatment programs (OTPs), the same clinics that dispense methadone. In that setting, the program orders medication under its own DEA registration and dispenses it directly to patients on site. Patients receiving buprenorphine through an OTP are considered patients of the program rather than of any individual prescriber.
Buprenorphine for Pain vs. Opioid Use Disorder
The prescribing rules differ depending on why the medication is being used. The sublingual formulations (tablets and films placed under the tongue) are FDA-approved specifically for treating opioid use disorder. These are the products affected by the regulatory changes described above.
Buprenorphine also comes in forms designed for pain management. Transdermal patches and a specific low-dose sublingual product called Belbuca are FDA-approved for chronic pain. These formulations cannot legally be used to treat opioid use disorder. Any provider with a standard DEA registration can prescribe the pain formulations without any additional training beyond what’s already required for controlled substances. The distinction matters: the formulation and the indication determine which rules apply.
Telehealth Prescribing
Buprenorphine can currently be prescribed through telehealth without an in-person visit first. The DEA has extended pandemic-era telemedicine flexibilities that allow practitioners to prescribe buprenorphine after a video or even audio-only encounter. This is particularly significant for patients in rural areas or those who face transportation barriers.
Two final rules published in January 2025 specifically address buprenorphine prescribing via telemedicine on a more permanent basis, with an effective date of December 31, 2025. Until then, the more permissive temporary rules remain in place. Under current policy, a DEA-registered practitioner can prescribe buprenorphine remotely through an audio-video telemedicine visit, and for opioid use disorder specifically, even audio-only encounters are permitted.
How to Find a Provider
Because the X-waiver is gone, there’s no longer a public registry of “waivered” providers the way there used to be. SAMHSA’s treatment locator at findtreatment.gov remains the most reliable tool for finding buprenorphine providers near you. Many primary care offices, urgent care clinics, and community health centers now offer it. If your regular doctor has a DEA registration, they may be able to prescribe it directly, even if addiction treatment isn’t their primary focus.
Buprenorphine is classified as a Schedule III controlled substance, which means prescriptions can include refills (unlike Schedule II medications, which require a new prescription each time). This makes ongoing treatment more convenient once you’ve established care with a provider.